AVEO Acquires Clinical Stage Anti-Cancer Compound From Kirin
Sat, 06 Jan 2007 08:00 AM EST
... AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, today announced it has acquired from Kirin Brewery Co., Ltd. an exclusive license to develop and commercialize Kirin's highly potent and selective, once-a-day, oral VEGF receptor inhibitor, KRN951, in all territories outside of Asia. [click link for full article] ...
Related Topics
- Clinical Trials
- Pancreatic Cancer
- Ovarian Cancer
- Cervical Cancer
- Lung Cancer
- Brain Cancer
- Colon Cancer
- Uterine Cancer
- Liver Cancer
- Small Cell Lung Cancer
- Prostate Cancer
- Pharmacology
- Kidney Cancer
- Esophageal Cancer
- Endometrial Cancer
- Aspirin and Carisoprodol
- Breast Cancer
- Stomach Cancer
- Rectal Cancer
- Colorectal Cancer

Not Signed In -


